We established a strategic collaboration with Sosei Heptares in 2016 to discover, develop and commercialise novel antibody therapeutics targeting G-protein-coupled receptors (GPCRs) with an initial focus on immuno-oncology.
Under the agreement, Sosei Heptares will apply its StaR® platform to create stable antigens based on multiple GPCR targets that we select in partnership. Our Kymab teams then use our human antibody discovery platforms to generate antibodies in response to immunisation with these antigens.
Our proprietary IntelliSelect™ platforms assure the highest probability of finding fully-human antibodies with highly attractive drug properties. We are taking forward promising leads using the complementary skills, resources and development capabilities of the two companies, in order to bring innovative products into the clinic. Our KY1051 CXCR4 product candidate is progressing as part of this collaboration.